VGX-1027
Appearance
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C11H11NO3 |
Molar mass | 205.213 g·mol−1 |
3D model (JSmol) | |
| |
|
VGX-1027 (GIT-27) is a drug which acts as an immunomodulator. It acts by blocking downstream signalling of the Toll-like receptors TLR2, TLR4 and TLR6, and thereby reducing production of various cytokines, including interleukins and TNF-α. In animal studies it has antiinflammatory effects and has been investigated for conditions such as arthritis and lung inflammation.[1][2][3][4][5][6]
References
[edit]- ^ Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D, Wang M, et al. (June 2007). "In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models". Clinical Immunology. 123 (3): 311–23. doi:10.1016/j.clim.2007.03.004. PMID 17449326.
- ^ Cha JJ, Hyun YY, Lee MH, Kim JE, Nam DH, Song HK, et al. (June 2013). "Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice". Endocrinology. 154 (6): 2144–55. doi:10.1210/en.2012-2080. PMID 23568555.
- ^ Saurus P, Kuusela S, Lehtonen E, Hyvönen ME, Ristola M, Fogarty CL, et al. (May 2015). "Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway". Cell Death & Disease. 6 (5): e1752. doi:10.1038/cddis.2015.125. PMC 4669704. PMID 25950482.
- ^ Lee JC, Menacherry S, Diehl MC, Giffear MD, White CJ, Juba R, et al. (March 2016). "Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjects". Clinical Pharmacology in Drug Development. 5 (2): 91–101. doi:10.1002/cpdd.193. PMID 27138022. S2CID 22577185.
- ^ Xu M, Li F, Wang M, Zhang H, Xu L, Adcock IM, et al. (January 2019). "Protective effects of VGX-1027 in PM2.5-induced airway inflammation and bronchial hyperresponsiveness". European Journal of Pharmacology. 842: 373–383. doi:10.1016/j.ejphar.2018.11.010. hdl:10044/1/66292. PMID 30419239. S2CID 53292202.
- ^ Ahmad SF, Nadeem A, Ansari MA, Bakheet SA, Alasmari F, Alasmari AF, et al. (November 2019). "The potent immunomodulatory compound VGX-1027 regulates inflammatory mediators in CD4+ T cells, which are concomitant with the prevention of neuroimmune dysregulation in BTBR T+ Itpr3tf/J mice". Life Sciences. 237: 116930. doi:10.1016/j.lfs.2019.116930. PMID 31610190. S2CID 204702143.